Aspen Pharmacare: Sean Capazorio

Sean Capazorio has been Aspen Group Finance Officer since January 1999.

Interview: 10 Questions to Sean Capazorio 2012.
                  8 Questions to Sean Capazorio 2018.

Sean Capazorio completed his articles at PwC and remained at the company post-articles for two years as an Audit Manager He also completed an advanced certificate in taxation at UNISA during this time. In 1993 he left the profession and joined Unisys as a Corporate Management Accountant. He was later promoted to the position of Financial Controller before leaving the company in 1996. He joined SAD as a Corporate Finance Accountant responsible for group taxation and corporate finance. He was appointed CFO of Aspen Pharmacare in January 1999. He has a B.Com and B.Acc from the University of the Witwatersrand. He is a CA(SA). 

Sean was awarded the Finance Transformation Award at the 2018 CFO Awards. 

Work
1999 – Present    Group Finance Officer, Aspen Pharmacare
1996 – 1998         Corporate Finance Accountant, South African Druggists 
1993 – 1996         Financial Controller, Corporate Management Accountant,                                            Unisys
1991 – 1993         Audit Manager, PwC
1987 – 1990         Articled Clerk, PwC

Education
1991 – 1992         Advanced Certificate in Taxation, UNISA
1986 – 1987         B.Acc, University of the Witwatersrand
1983 – 1985         B.Com, University of the Witwatersrand

About Aspen Pharmacare: As a leading global player in specialty, branded and generic pharmaceuticals, Aspen have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. They continue to increase the number of lives benefiting from their products that reach more than 150 countries. 

They hold international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines. Their manufacturing capabilities are scaleable to demand and cover a wide variety of product types including oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceutical ingredients and nutritionals. Aspen has a strong presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. The group supplies medicines and products to more than 150 countries.

They have more than 10 000 employees and reported a revenue of R41.2 billion in 2017.